Simulating Dynamic Tumor Contrast Enhancement in Breast MRI using Conditional Generative Adversarial Networks
Richard Osuala, Smriti Joshi, Apostolia Tsirikoglou, Lidia Garrucho, Walter H. L. Pinaya, Daniel M. Lang, Julia A. Schnabel, Oliver Diaz, Karim Lekadir
TL;DR
This work addresses the need for non-invasive breast cancer imaging by synthesizing dynamic DCE-MRI sequences from non-contrast MRI via a conditional GAN framework. It introduces the Scaled Aggregate Measure (SAMe) to unify multiple quality metrics and demonstrates both single-sequence and joint multi-timepoint DCE-MRI generation, evaluating their utility for tumor segmentation. Across experiments on the Duke dataset, synthetic post-contrast images closely resemble real post-contrast data and can improve segmentation performance, especially under domain shift, while joint timepoint generation captures clinically relevant contrast-kinetics patterns. The approach holds promise for CA-free screening and robust training data augmentation, with potential to enhance diagnostic workflows and patient safety in breast cancer management.
Abstract
This paper presents a method for virtual contrast enhancement in breast MRI, offering a promising non-invasive alternative to traditional contrast agent-based DCE-MRI acquisition. Using a conditional generative adversarial network, we predict DCE-MRI images, including jointly-generated sequences of multiple corresponding DCE-MRI timepoints, from non-contrast-enhanced MRIs, enabling tumor localization and characterization without the associated health risks. Furthermore, we qualitatively and quantitatively evaluate the synthetic DCE-MRI images, proposing a multi-metric Scaled Aggregate Measure (SAMe), assessing their utility in a tumor segmentation downstream task, and conclude with an analysis of the temporal patterns in multi-sequence DCE-MRI generation. Our approach demonstrates promising results in generating realistic and useful DCE-MRI sequences, highlighting the potential of virtual contrast enhancement for improving breast cancer diagnosis and treatment, particularly for patients where contrast agent administration is contraindicated.
